Maxcyte Stock Performance
| MXCT Stock | USD 3.52 0.14 4.14% |
The company secures a Beta (Market Risk) of 1.38, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, MaxCyte will likely underperform. At this point, MaxCyte has a negative expected return of -0.26%. Please make sure to verify MaxCyte's potential upside, rate of daily change, as well as the relationship between the Rate Of Daily Change and period momentum indicator , to decide if MaxCyte performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days MaxCyte has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's fundamental indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Actual Historical Performance (%)
One Day Return 4.14 | Five Day Return 2.03 | Year To Date Return (29.60) | Ten Year Return (79.29) | All Time Return (79.29) |
1 | Disposition of 25000 shares by Soleymannezhad Ali of MaxCyte at 5.02 subject to Rule 16b-3 | 09/11/2024 |
2 | Acquisition by Soleymannezhad Ali of 20800 shares of MaxCyte at 4.12 subject to Rule 16b-3 | 09/16/2024 |
3 | Disposition of 26082 shares by Erck Stanley C of MaxCyte at 0.04 subject to Rule 16b-3 | 10/01/2024 |
4 | MaxCyte Inc Q2 2024 Earnings Call Highlights Revenue Growth Amid Core Challenges | 10/09/2024 |
5 | MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024 | 10/11/2024 |
6 | Insider Trading | 10/14/2024 |
7 | Acquisition by Swirsky Douglas J of 81250 shares of MaxCyte subject to Rule 16b-3 | 10/18/2024 |
8 | Disposition of 3000 shares by Johnston John Joseph of MaxCyte at 2.926 subject to Rule 16b-3 | 10/28/2024 |
9 | MaxCyte director Johnston sells 11,166 in stock | 10/30/2024 |
10 | Disposition of 47689 shares by Erck Stanley C of MaxCyte at 0.04 subject to Rule 16b-3 | 11/01/2024 |
11 | MaxCyte Inc Q3 2024 Earnings Revenue Surpasses Estimates at 8.2M, EPS of -0. ... | 11/06/2024 |
12 | Q3 2024 MaxCyte Inc Earnings Call Transcript | 11/07/2024 |
13 | MaxCyte Third Quarter 2024 Earnings Beats Expectations | 11/08/2024 |
14 | CADIAN CAPITAL MANAGEMENT, LP Expands Stake in MaxCyte Inc | 11/14/2024 |
15 | This MaxCyte Insider Increased Their Holding In The Last Year | 11/21/2024 |
| Begin Period Cash Flow | 11.1 M |
MaxCyte |
MaxCyte Relative Risk vs. Return Landscape
If you would invest 432.00 in MaxCyte on August 30, 2024 and sell it today you would lose (80.00) from holding MaxCyte or give up 18.52% of portfolio value over 90 days. MaxCyte is currently does not generate positive expected returns and assumes 3.3307% risk (volatility on return distribution) over the 90 days horizon. In different words, 29% of stocks are less volatile than MaxCyte, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
MaxCyte Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for MaxCyte's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as MaxCyte, and traders can use it to determine the average amount a MaxCyte's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0793
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | MXCT |
Estimated Market Risk
| 3.33 actual daily | 29 71% of assets are more volatile |
Expected Return
| -0.26 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.08 actual daily | 0 Most of other assets perform better |
Based on monthly moving average MaxCyte is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of MaxCyte by adding MaxCyte to a well-diversified portfolio.
MaxCyte Fundamentals Growth
MaxCyte Stock prices reflect investors' perceptions of the future prospects and financial health of MaxCyte, and MaxCyte fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on MaxCyte Stock performance.
| Return On Equity | -0.16 | ||||
| Return On Asset | -0.11 | ||||
| Profit Margin | (0.78) % | ||||
| Operating Margin | (1.72) % | ||||
| Current Valuation | 233.16 M | ||||
| Shares Outstanding | 105.48 M | ||||
| Price To Book | 1.74 X | ||||
| Price To Sales | 8.14 X | ||||
| Revenue | 41.29 M | ||||
| Gross Profit | 39.16 M | ||||
| EBITDA | (44.13 M) | ||||
| Net Income | (37.92 M) | ||||
| Cash And Equivalents | 240.89 M | ||||
| Cash Per Share | 2.37 X | ||||
| Total Debt | 18.74 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 14.24 X | ||||
| Book Value Per Share | 2.03 X | ||||
| Cash Flow From Operations | (21.69 M) | ||||
| Earnings Per Share | (0.34) X | ||||
| Market Capitalization | 371.3 M | ||||
| Total Asset | 268.27 M | ||||
| Retained Earnings | (175.8 M) | ||||
| Working Capital | 172.34 M | ||||
About MaxCyte Performance
Assessing MaxCyte's fundamental ratios provides investors with valuable insights into MaxCyte's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the MaxCyte is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 941.29 | 988.35 | |
| Return On Tangible Assets | (0.14) | (0.15) | |
| Return On Capital Employed | (0.19) | (0.18) | |
| Return On Assets | (0.14) | (0.15) | |
| Return On Equity | (0.16) | (0.16) |
Things to note about MaxCyte performance evaluation
Checking the ongoing alerts about MaxCyte for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for MaxCyte help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| MaxCyte generated a negative expected return over the last 90 days | |
| MaxCyte has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 41.29 M. Net Loss for the year was (37.92 M) with profit before overhead, payroll, taxes, and interest of 39.16 M. | |
| MaxCyte currently holds about 240.89 M in cash with (21.69 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.37. | |
| MaxCyte has a poor financial position based on the latest SEC disclosures | |
| Roughly 71.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: This MaxCyte Insider Increased Their Holding In The Last Year |
- Analyzing MaxCyte's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether MaxCyte's stock is overvalued or undervalued compared to its peers.
- Examining MaxCyte's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating MaxCyte's management team can have a significant impact on its success or failure. Reviewing the track record and experience of MaxCyte's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of MaxCyte's stock. These opinions can provide insight into MaxCyte's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for MaxCyte Stock Analysis
When running MaxCyte's price analysis, check to measure MaxCyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MaxCyte is operating at the current time. Most of MaxCyte's value examination focuses on studying past and present price action to predict the probability of MaxCyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MaxCyte's price. Additionally, you may evaluate how the addition of MaxCyte to your portfolios can decrease your overall portfolio volatility.